Encapsulated papillary oncocytic neoplasms of the thyroid: Morphologic, immunohistochemical, and molecular analysis of 18 cases

American Journal of Surgical Pathology

Volumn 34, Issue 11, 2010, Pages 1582-1590

  Woodford, Randall Lyndon ^a   Nikiforov, Yuri E ^b   Hunt, Jennifer L ^c   Bellizzi, Andrew M ^d   Zhang, Xiaotang ^e   Mills, Stacey E ^a   Stelow, Edward B ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

BRAF mutation; CD56; CK19; HBME1; H rthle cell; immunohistochemistry; oncocytic; papillary; thyroid

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; CD56 ANTIGEN; CYTOKERATIN 19; HBME 1 ANTIGEN; HBME-1 ANTIGEN; PROTEIN RET; RET PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOMA; CHEMISTRY; CLASSIFICATION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MORTALITY; NOMENCLATURE; ONCOCYTOMA; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; THYROID TUMOR;

ADENOMA, OXYPHILIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; CARCINOMA; EXONS; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATIN-19; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; TERMINOLOGY AS TOPIC; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78049530593     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181f2d820     Document Type: Article

References (49)

1. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222.
2. Asa SL. My approach to oncocytic tumours of the thyroid. J Clin Pathol. 2004;57:225-232.
3. Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34:44-52.
4. Beckner ME, Heffess CS, Oertel JE. Oxyphilic papillary thyroid carcinomas. Am J Clin Pathol. 1995;103:280-287.
5. Berho M, Suster S. The oncocytic variant of papillary carcinoma of the thyroid: a clinicopathologic study of 15 cases. Hum Pathol. 1997; 28:47-53.
6. Bongarzone I, Fugazzola L, Vigneri P, et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996;81: 2006-2009.
7. Carcangiu ML, Bianchi S, Savino D, et al. Follicular Hurthle cell tumors of the thyroid gland. Cancer. 1991;68:1944-1953.
8. Cheung CC, Ezzat S, Ramyar L, et al. Molecular basis off hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab. 2000;85: 878-882.
9. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
11. De Lellis RA, Lloyd RV, Heitz PU, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004.
12. El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol. 2008;3:5.
13. El Demellawy D, Nasr AL, Babay S, et al. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract. 2009;205:303-309.
14. Ewing J. Neoplastic Diseases; A Treatise on Tumors. Philadelphia, PA; London: WB Saunders; 1928.
15. Fenton CL, Lukes Y, Nicholson D, et al. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab. 2000;85:1170-1175.
16. Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995;55:5617-5620.
17. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455-6457.
18. Fusco A, Grieco M, Santoro M, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature. 1987;328:170-172.
19. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/ PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646-6656.
20. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60: 557-563.
21. Gundry SR, Burney RE, Thompson NW, et al. Total thyroidectomy for Hurthle cell neoplasm of the thyroid. Arch Surg. 1983;118: 529-532.
22. Hedinger CE, Williams ED, Sobin LH. Histological Typing of Thyroid Tumours. Berlin; New York, NY: Springer-Verlag; 1988.
23. Herrera MF, Hay ID, Wu PS, et al. Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg. 1992;16:669-674; discussion 774-775.
24. Jakubowski M, Hunt JL. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. Am J Surg Pathol. 2009;33:1590-1593.
25. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007; 246:466-470; discussion 470-471.
26. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
27. Klugbauer S, Lengfelder E, Demidchik EP, et al. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene. 1995;11:2459-2467. (Pubitemid 26023813)
28. Mai KT, Bokhary R, Yazdi HM, et al. Reduced HBME-1 immuno-reactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology. 2002;40:133-142.
29. Migita K, Eguchi K, Kawakami A, et al. Detection of Leu-19 (CD56) antigen on human thyroid epithelial cells by an immuno-histochemical method. Immunology. 1991;72:246-249.
30. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393-4397.
31. Nasr MR, Mukhopadhyay S, Zhang S, et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006; 19:1631-1637.
32. Nga ME, Lim GS, Soh CH, et al. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol. 2008;36:550-556.
33. Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690-1694.
34. Rabes HM, Demidchik EP, Sidorow JD, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res. 2000;6:1093-1103.
35. Rosai J. Rosai and Ackerman's Surgical Pathology. 9th ed. Edinburgh; New York, NY: Mosby; 2004.
36. Rosai J, Carcangiu ML, DeLellis RA. Atlas of Tumor Pathology. Third Series, Fascicle Five. Tumors of the Thyroid Gland. Washington, DC: Armed Forces Institute of Pathology; 1992.
37. Sahoo S, Hoda SA, Rosai J, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol. 2001;116:696-702.
38. Scarpino S, Di Napoli A, Melotti F, et al. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol. 2007;212:411-419.
39. Schelfhout LJ, Van Muijen GN, Fleuren GJ. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma. Am J Clin Pathol. 1989;92:654-658.
40. Scognamiglio T, Hyjek E, Kao J, et al. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006;126: 700-708.
41. Smida J, Salassidis K, Hieber L, et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer. 1999;80:32-38.
42. Soares P, Fonseca E, Wynford-Thomas D, et al. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol. 1998;185: 71-78.
43. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/ PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
44. Thompson NW, Dunn EL, Batsakis JG, et al. Hurthle cell lesions of the thyroid gland. Surg Gynecol Obstet. 1974;139:555-560.
45. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 2004;202:247-251.
46. Wenig BM. Atlas of Head and Neck Pathology. Philadelphia, PA, London: Elsevier Saunders; 2008.
47. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561-4567.
48. Zeromski J, Bagnasco M, Paolieri F, et al. Expression of CD56 (NKH-1) differentiation antigen in human thyroid epithelium. Clin Exp Immunol. 1992;89:474-478.
49. Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab. 2006;91:3603-3610.